Merck may be near NuvaRing settlement

Share this article:

Merck may be poised to settle lawsuits over its NuvaRing contraceptive for $100 million—a bargain, Bloomberg notes, compared to drugmakers such as Bayer, which has paid more than $1.6 billion over claims surrounding its birth control pills Yaz and Yazmin.

Women and families have sued the company, saying the drugmaker knew the contraceptive triggered a higher risk of heart attack and blood clots than competing products. Merck told Bloomberg that the proposed settlement is not an admission of wrongdoing and the company stands behind the contraceptive.

Ninety-five percent of the 3,800 plaintiffs need to agree to the settlement or Merck can walk away.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.